(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 September 2005 (29.09.2005)

PCT

(10) International Publication Number
WO 2005/090331 A1

(51) International Patent Classification[7]: C07D 401/14

(21) International Application Number:
PCT/IB2005/000616

(22) International Filing Date: 4 March 2005 (04.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/554,140 17 March 2004 (17.03.2004) US

(71) Applicant *(for all designated States except US)*: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **YE, Qiang** [US/US]; Pfizer Global Research and Development, 10777 Science Center Drive, San Diego, CA 92121 (US). **ZOOK, Scott, Edward** [CA/US]; 3716 Arizona Street, San Diego, CA 92104 (US). **OUELLETTE, Michael, Allen** [US/US]; 9727 Chiquita Road, Descanso, CA 91916 (US). **HETTINGER, Donald, Nicholas** [US/US]; 4115 Twilight Ridge, San Diego, CA 92130 (US). **SRIRANGAM, Jayaram, Kasturi** [US/US]; Pfizer Global Research and Development, 10777 Science Center Drive, San Diego, CA 92121 (US). **KANIA, Robert, Steven** [US/US]; Pfizer Global Research and Development, 10777 Science Center Drive, San Diego, CA 92121 (US). **SAEED, Nabil, Lauze** [US/US]; Pfizer Global Research and Development, 10777 Science Center Drive, San Diego, CA 92121 (US). **WIGHTLIN, Matthew, David** [US/US]; 4194 Texas Street, San Diego, CA 92104 (US). **MITCHELL, Mark, Bryan** [GB/US]; Pfizer Global Research and Development, 10777 Science Center Drive, San Diego, CA 92121 (US).

(74) Agents: **FULLER, Grover, F. Jr.** et al.; Pfizer Inc., 201 Tabor Road, Morris Plains, NJ 07950 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: POLYMORPHIC AND AMORPHOUS FORMS OF 2,5-DIMETHYL-2H-PYRAZOLE-3-CARBOXYLIC ACID {2-FLUORO-5-[3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDASOL-6-YLAMINO]-PHENYL}-AMIDE

(57) Abstract: The invention provides several polymorphic forms and an amorphous form of 2,5-Dimethyl-2H-pyrazole-3-carboxylic acid {2-fluoro-5-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6ylamino]-phenyl}-amide, pharmaceutical compositions containing such polymorphic or amorphous forms, and methods of using such pharmaceutical compositions to treat disease states mediated by protein kinases, such as cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation.

WO 2005/090331 A1